pentosan polysulphate sodium
Commercial- Indications
- Thrombosis, Blood clotting disorders
Company intelligence / Profile preview
Bene pharmaChem manufactures the active pharmaceutical ingredient pentosan polysulfate sodium (PPS), a sulphated polysaccharide with anticoagulant, fibrinolytic, and anti-inflammatory properties. PPS has been used clinically for over six decades as an antithrombotic agent in Europe and forms the basis of Elmiron®, the first EU-approved drug therapy for bladder pain syndrome/interstitial cystitis. The company supplies PPS to partners globally; its product pipeline includes both commercialized APIs and licensed programs under development by partners such as Paradigm Biopharma, which is running Phase III trials of injectable PPS for knee osteoarthritis.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Bene pharmaChem.